摘要
目的研究恩替卡韦+胸腺肽治疗乙型肝炎肝硬化的效果及不良反应。方法选取2017年1月~2018年1月聊城市人民医院收治的乙型肝炎肝硬化患者作为本研究对象,根据随机抽签分组方式将100例乙型肝炎肝硬化患者进行分组,其中观察组实施恩替卡韦+胸腺肽治疗;对照组实施恩替卡韦治疗,将两组肝功能指标、肝纤维化四项数值、治疗效果和不良反应情况进行比较。结果观察组患者治疗后TB(20.03±1.52)μmol/L、ALT(22.12±1.32)IU/L、ALB(39.82±1.24)g/L与对照组比较,差异有统计学意义(P<0.05)。两组患者肝纤维化四项数值比较,前者更低(P<0.05)。观察组患者治疗总有效率(98.00%)高于对照组(P<0.05)。两组患者不良反应发生率比较,前者更低(P<0.05)。结论恩替卡韦+胸腺肽治疗乙型肝炎肝硬化的效果显著,且安全性高,值得研究和推广。
Objective To study the effect and adverse reactions of entecavir+thymosin in the treatment of hepatitis B cirrhosis.Methods A total of 100 patients with hepatitis B cirrhosis treated in Liaocheng People's Hospital from January 2017 to January 2018 were selected as the subjects in this study.They were divided into two groups according to their random lottery grouping method.The observation group was treated with entecavir+thymosin,while the control group was treated with entecavir.The liver function indicators,liver fibrosis values,treatment effects and adverse reactions were compared between the two groups.Results After treatment,total bilirubin(TB)(20.03±1.52)μmol/L,alanine aminotransferase(ALT)(22.12±1.32)IU/L,and albumin(ALB)(39.82±1.24)g/L in the observation group were statistically different from those in the control group(P<0.05).The four values of liver fibrosis in the observation group were lower than those in the control group(P<0.05).The total effective rate of the observation group was 98.00%,which was higher than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion The application of entecavir+thymosin is effective in the treatment of hepatitis B cirrhosis and has higher safety.It is worthy of research and promotion.
作者
刘雪妮
刘春华
亓梅
LIU Xueni;LIU Chunhua;QI Mei(Department of Infectious Diseases,Shandong Ear,Nose and Throat Hospital,Shandong,Ji'nan 250022,China;Department of Infectious Diseases,Liaocheng People's Hospital,Shandong,Liaocheng 252000,China;Department of Respiratory and Critical Care Medicine,Shandong Ear,Nose and Throat Hospital,Shandong,Ji'nan 250022,China)
出处
《中国医药科学》
2020年第11期62-65,共4页
China Medicine And Pharmacy
